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rBifurcated Aortic Stent Grafts Are Safe and Effective for Endovascular
Repair of Aortic Aneurysms in Patients With NarrowDistal Aortic Bifur-
cations: Aorto-Iliac Converters Are Rarely Needed in the Current Era
Veljko Strajina, MD, Gustavo S. Oderich, MD, Javariah Fatima, MD, Peter
Gloviczki, MD, Audra A. Duncan, MD, Manju Kalra, MBBS, Mark Flem-
ming,MD, Thanila A.Macedo,MD, Thomas C. Bower, MD. Mayo Clinic,
Rochester, Minn
Objectives: Endovascular aortic aneurysm repair (EVAR) in patients
with narrow distal aortic bifurcations can be complicated by inability to
access the contralateral gate, iliac limb compression, or aortic disruption.
This study analyzes outcomes of EVAR using bifurcated stent grafts or
aortouniiliac converters in patients with narrow distal aortic bifurcation.
Methods: We reviewed the clinical data of 1070 patients who under-
went EVAR between 2000 and 2011. Digital computed tomographic
angiography (CTA) was analyzed using centerline of flow measurements to
determine aortic diameters. Patients with diameter 18 mm at the distal
aortic bifurcation (AoB) were included in the study. End points were
technical success, aortic disruption with retroperitoneal hemorrhage, stent
graft complications (endoleaks, migration, sac enlargement, stenosis), rein-
tervention, and iliac limb patency.
Results: There were 112 patients (84 men and 28 women; mean age,
75 years) with AoB18mm treated by EVAR, including 34 (30%) who had
diameter of 14 mm. Mean outer and inner AoB diameter was 16  3 and
14  2 mm, respectively. Bifurcated stent grafts were used in 106 patients
(95%). Six patients (5%) treated before 2005 had planned aortouniiliac
converter with femoral crossover graft. The AoB was dilated after placement
of bifurcated stent grafts using kissing balloon angioplasty in 80 patients
(75%). All bifurcated stent grafts were successfully implanted, with no
conversions to open repair or aortouniiliac converters. There was one early
death (0.8%), and 12 patients (11%) developed early complications. There
were no aortic disruptions or retroperitoneal hematomas. After a median
follow-up of 34 months, 11 patients (11%) treated by bifurcated stent grafts
required reintervention to treat endoleak (n  6) or iliac limb stenosis/
occlusion (n  5). One patient (17%) treated by aortouniiliac converter
required femoral crossover graft revision for restenosis. At 3 years, freedom
from stent graft complication or reintervention was 91% 6% and 91% 6%
for bifurcated stent grafts, and 83% 10% and 83% 10% for aortouniiliac
converters (P  NS). Primary and secondary iliac limb patency was 98% 
3% and 100% for bifurcated stent grafts and 83%  10% and 100% for
aortouniiliac converters, respectively (P  NS).
Conclusions: Endovascular aortic aneurysm repair in patients with
narrow distal aortic diameter is safe and effective using bifurcated stent
grafts, even when the aortic bifurcation measures 14 mm. Using adjunc-
tive balloon dilatation, there were no bleeding complications from aortic
disruption, and limb patency was excellent. Aortouniiliac converters are
rarely needed for this indication.
Intact Abdominal Aortic Aneurysm (AAA) Repair Is Not Appropriate
in Patients on Dialysis
Joseph Sidaoui, MD, Larry Fish, PhD, Theodore Yuo, MD, Luke Marone,
MD, Michel Makaroun, MD, Rabih Chaer, MD. University of Pittsburgh
Medical Center, Pittsburgh, Pa
Objectives: Abdominal aortic aneurysm (AAA) repair in the general
population is effective, with reported mortality rates of10% at 1 year. The
outcomes of AAA repair in patients on dialysis are not well characterized,
with a questionable survival advantage in such patients with limited life
expectancy. The purpose of this study is to report the outcomes of AAA
repair in United States dialysis patients.
Methods: The United States Renal Data System (USRDS) was used to
collect data on intact asymptomatic AAA repair in all dialysis patients in the
United States from the 2005 to 2008 Physician Services data files. Elective
endovascular aneurysm repair (EVAR) and open repair were identified by
CPT codes. Primary outcomes were the perioperative (30-day) mortality
and long-term survival. Bivariate associations were tested using the 2 test,
and predictors of mortality were identified using regression models.
Results: Of 2,260,986 dialysis patients, 1557 aged 30 years older
had an AAA repair (0.05%): 261 open and 1296 EVAR (Table). The 30-day
mortality was 11.5% (10.5% EVAR, 16.22% open, P .009). The mortality
rate 1 year after AAA repair was 39.0% (39.3% EVAR, 37.7% open; P .65).
Kaplan-Meier estimates of survival were 66.5% at 1 year (66.2% EVAR,
67.5% open; P .78), and only 37.4% at 3 years (36.8% EVAR, 39.8% open;
P  .65). Women had a higher overall mortality rate at 1 year (43.1%) than
men (37.4%; P  .06). There was no significant 1-year mortality difference
when comparing type of procedure inmen (EVAR, 37.4%; open, 37.6%; P
.95) and in women (EVAR, 44.4%, open, 37.7%; P  .31). By logistic
regression, older age in years (OR, 1.03; 95% CI, 1.02-1.05; P .001), less
time on dialysis in months (OR, 0.99; 95% CI, 0.981-1.00; P  .001),
absence of a transplant (OR, 0.30; 95% CI, 0.20-0.45; P  .001); diabetes
(OR, 1.75; 95% CI, 1.18-2.60, P  .006), absence of hypertension (OR,
0.54; 95%CI, 0.34-0.85; P .008), and bodymass index (OR, .96; 95%CI,
T
s.93-0.98; P  .002) had significant associations with mortality within the
bservation period.
Conclusions:AAApatients on dialysis have high perioperative and 1-year
ortality rates after EVAR or open repair. This questions the indications for
ntact AAA repair in dialysis patients, especially in diabetic individuals, women,
r older patients. AAA repair in dialysis patients may have to be restricted to
atients with larger aneurysms, especially if open repair is required (Table).





ge (in years, mean 
SD)
69.9  9.9 69.9  10.6 .99
ex (M/F) 188 (72.0)/73 (30.0) 963 (74.3)/333(25.7) .45
emodialysis/peritoneal
dialysis
222 (94.5)/13 (5.5) 1091 (92.7)/86 (7.3) .33
iabetes 41 (25.6) 201 (25.2) .89
istory of transplant 42 (16.1) 260 (20.1) .14
schemic heart disease 53 (33.1) 275 (34.4) .76
VATIA 17 (10.6) 84 (10.5) .96
VD 24 (15.0) 165 (20.6) .10
ypertension 128 (80.0) 655 (81.9) .58
mokers 16 (10.0) 71 (8.9) .65
resence of neoplasm 3 (1.9) 39 (4.9) .09
ime on dialysis (in
years, mean  SD)
4.2  2.5 4.5  3.0 .22
MI (mean  SD) 25.9  5.9 26.6  5.9 .11
Because of missing data, Ns vary considerably among rows.
ne-Year Safety and Efficacy of Thoracic Aortic Stent Grafting
TEVAR) in PatientsWhoAre PoorOpen Surgical Candidates: Results
f the High-Risk Arm of the Valor Trial
ark F. Conrad, MD,1 Ronald M. Fairman, MD,2 Richard P. Cambria,
D,1 Mark Farber, MD,3 Alan Matsumoto, MD,4 David Williams, MD,5
rank J. Criado, MD,6 Christopher J. Kwolek, MD1. 1Massachusetts Gen-
ral Hospital, Boston, Mass; 2University of Pennsylvania Hospital, Philadel-
hia, Pa; 3University of North Carolina, Chapel Hill, NC; 4University of
irginia, Charlottesville, Va; 5University of Michigan, Ann Arbor, Mich;
Union Memorial Hospital, Baltimore, Md
Objectives: The high-risk arm of the Valor trial was designed to
nclude patients who are poor open surgical candidates, have an acute aortic
issection with malperfusion syndrome or impending aortic rupture, and
raumatic aortic injuries. The 1-year results of this trial are reported.
Methods: This is a prospective, nonrandomized, multicenter trial de-
igned to evaluate the safety and efficacy of TEVAR for several high-risk aortic
athologies. Primary end points included all-cause mortality and successful
neurysm exclusion at 30 days and 1 year. Secondary outcomes were freedom
rom major adverse events (MAE) and secondary procedures at 1 year.
Results:The study enrolled 137patients, comprising 102 (75%) high-risk
neurysms, 18 (13%) dissections, and 17 (12%) traumatic injuries. Clinical
actors include average age of 72 years, 58% male, 20% diabetic, 48% with
oronary disease, and 46% symptomatic. The paraplegia rate was 0.7% (1 of
37) and the stroke ratewas 9% (12 of 137), with no difference by etiology. The
0-day mortality was 7% (12% trauma, 6% aneurysm, 11% dissection), whereas
he 1-yearmortality rate was 25% (33% dissection, 25% aneurysm, 18% trauma).
redictors of all-cause mortality included cerebrovascular accident, paraplegia,
nd renal insufficiency. The 1-year aneurysm-related mortality was 11%; there
ere three aneurysm ruptures. Most deaths in the dissection cohort (5 of 6)
ere aneurysm related. Secondary procedures were performed in 14 patients
10%); 86% (12 of 14) were for endoleak. MAE occurred in 88 patients (64%)
t 1 year, with 86% occurring in the first 30 days.
Conclusions: TEVAR can be accomplished with low mortality and
araplegia in patients who are poor open surgical candidates. MAEs are
requent, and the 1-year aneurysm-related death rate remains 11% in this
igh-risk population.
elative Importance of Aneurysm Diameter and Body Size for Predict-
ng AAA Rupture in Men and Women
uby C. Lo, MD,1 Bing Lu, MD/PhD,2 Mark F. Conrad, MD,3 Mark F.
illinger, MD,4 Robina Matyal, MD,1 Allen D. Hamdan, MD,1 Marc L.
chermerhorn, MD1. 1Beth Israel Deaconess Medical Center, Boston, Mass;
Brigham & Women’s Hospital, Boston, Mass; 3Massachusetts General Hos-
ital, Boston, Mass; 4Dartmouth-Hitchcock Medical Center, Lebanon, NH
Objectives: Women have an increased risk of abdominal aortic aneu-
ysm (AAA) rupture at any given aneurysm diameter compared with men.
he accepted 5.5-cm repair threshold was derived from natural history
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January 2013288 Abstractsrupture and aneurysm diameter relative to body size for men and women
with the goal of testing a novel method of rupture risk stratification that is
more appropriate for women.
Methods:We reviewed all patients in the Vascular Surgery Group of
New England database who underwent endovascular or open AAA
repair. We evaluated height, weight, body mass index (BMI), and body
surface area (BSA) as well as each of these values indexed to the aortic
diameter (eg, BSA index  aneurysm diameter (cm)/BSA [m2]). Along
with other relevant clinical variables, we constructed multivariable-ad-
justed logistic regression models using forward selection to determine
predictors of rupture repair vs elective repair. Models for men and women
were developed separately, and different models were compared using
the area under the curve (AUC).
Results:We identified 4045 patients who underwent AAA repair (11%
ruptured, 53% EVAR, 78% men). Women had significantly smaller diameter
aneurysms, lower BSA, and higher BSA indices than men (Table). For men,
the primary determinant of rupture was aneurysm diameter (AUC, 0.82):
55 mm (referent); 55-64 mm (OR, 0.9; 95% CI, 0.5-1.7; P  .771);
65-74 mm (OR, 3.9; 95% CI, 1.9-1.0; P .001); and75 mm (OR, 11.3;
95% CI, 4.9-25.8; P .001). In contrast, BSA index was most predictive of
rupture for women (AUC, 0.81), with higher odds of rupture at higher BSA
indices: 25 (OR, 3.9; 95% CI, 0.5-28.2; P  .175); 25-29 (OR, 3.3; 95%
CI, 0.8-14.5; P  .111); 30-34 (referent); 35-39 (OR, 6.4; 95% CI,
1.7-24.1; P  .006); and 40 (OR, 9.5; 95% CI, 2.3-39.4; P  .002). For
women, aneurysm diameter alone was not a significant predictor of rupture
after adjusting for BSA index.
Conclusions: Aneurysm diameter indexed to body size is the most
important determinant of rupture for women, whereas aneurysm diameter
alone is most predictive of rupture for men. Women with the largest
diameter aneurysms and the smallest body sizes are at the greatest risk of
rupture.





(n  907) P
Demographics
Age, mean (SD) years 71.9 (8.7) 74.3 (7.7) .001
Aneurysm diameter, mm .001
20-54, No. (%) 1032 (32.9) 368 (40.6)
55-64, No. (%) 1170 (37.3) 350 (38.6)
65-74, No. (%) 452 (14.4) 111 (12.2)
75, No. (%) 483 (15.4) 78 (8.6)
BSA, m2a .001
1.8, No. (%) 405 (12.9) 551 (60.7)
1.8-1.9, No. (%) 1073 (34.2) 258 (28.5)
2.0, No. (%) 1660 (52.9) 98 (10.8)
BSA index, cm/m2b .001
25, No. (%) 668 (21.3) 77 (8.5)
25-29, No. (%) 1136 (36.2) 231 (25.5)
30-34, No. (%) 678 (21.6) 297 (32.7)
35-39, No. (%) 342 (10.9) 171 (18.8)
40, No. (%) 314 (10.0) 132 (14.5)
Predictors of ruptured
repair OR (95% CI)c P OR (95% CI)d P
Aneurysm diameter, mm
20-54, % 1.0 1.0
55-64, % 0.9 (0.5-1.7) .8 1.1 (0.3-3.7) .85
65-74, % 3.9 (1.9-8.0) .01 3.3 (0.8-12.7) .09
75, % 11.3 (4.9-25.8) .01 3.2 (0.7-14.5) .13
BSA Index, cm/m2b
25, % 0.6 (0.3-1.4) .23 3.9 (0.5-28.2) .18
25-29, % 0.8 (0.5-1.5) .53 3.3 (0.8-14.5) .11
30-34, % 1.0 1.0
35-39, % 0.8 (0.5-1.4) .52 6.4 (1.7-24.1) .01
40, % 1.4 (0.8-2.6) .2 9.5 (2.3-39.4) .01
aBSA  BSA (m2)  0.20247  Height (m)0.725 Weight (kg)0.425.
bBSA index  aneurysm diameter (cm)/BSA (m2).
cArea under the curve  0.82.
dArea under the curve  0.81.
A 20-Year Experience With Endovascular Repair of Abdominal Aortic
Aneurysms: A Record of the Development and Evolution of Tech-
niques, Devices, and Strategies
Rami O. Tadros, MD, Peter L. Faries, MD, Hannah L. Lowe, MD, Rachel
Schrier, MD, Robert A. Lookstein, MD, Sung yup P. Kim, MD, Jamie Kim,
MD, Ageliki G. Vouyouka, MD, Sharif H. Ellozy, MD, Michael L. Marin,
MD. The Mount Sinai School of Medicine, New York, NY
e
FObjectives: Endovascular repair of abdominal aortic aneurysms (EVAR)
as become the first-line treatment of abdominal aortic aneurysms (AAA)
orldwide. Since the first successful EVAR in North America, the authors have
aintained a continuous, prospective database recording the details of each
rocedure.
Methods: Between 1992 and 2012, 1268 patients (mean age, 75 years;
5% men) underwent EVAR for repair of AAA. Fifteen different types of stent
rafts were used (Table). Eighty-one percent of patients exhibited high-risk
haracteristics that would preclude participation in Food andDrug Administra-
ion-mandated, industry sponsored-IDE pivotal trials. Ninety-three percent of
atients had at least one severe comorbid medical condition, with an average of
.2 conditions per patient. During EVAR, 38% had concomitant treatment
f associated common iliac artery aneurysms.Mean follow-up was 38.2 months.
Results: Major perioperative complications occurred in 7.5%, with a
erioperative mortality rate of 2.5%. Aneurysm size remained stable or
ecreased (5 mm) in 86.5% of patients and increased (5 mm) in 13.5%;
edian time to aneurysm expansion was 8.2 years. During follow-up, type I
ndoleak occurred in 2.1% of patients and type III in 0.2%. Reintervention
as required in 21% of patients.Mean time to reintervention was 26months.
reedom from aneurysm-related mortality was 91.1% at 12 years. Median
urvival for all-cause mortality was 5.6 years.
Conclusions: Progressive advances in EVAR allow safe, effective, and
urable repair of AAA, extending the instructions for use parameters of
ommercially available devices.
able 1. Operative data
Mean SD
nesthesia time (hours) 5.05  1.51
urgery time (hours) 3.70  1.47
stimated blood loss (mL) 367.8  515.3
ransfusion volume (mL) 645.3  647.4
ength of hospitalization (days) 2.75  5.96
nitial aneurysm size (cm) 5.9  1.2
neurysm size at latest F/U (cm) 5.5  1.6
No. of patients %
re-operative adjunctive procedure(s) 438 34.6%
atients receiving transfusion 181 14.3%
eneral anesthesia 75 5.9%
pinal or epidural anesthesia 1085 85.8%
ube graft 59 4.7%
ifurcated graft 992 78.2%
orto-uni-iliac graft 207 16.3%
hysician-made EVSGs 109 8.6%
ndustry-made EVSGs 1159 91.4%
ischarge on postoperative day 0 or 1 802 63.4%
ajor perioperative complications 95 7.5%
erioperative mortality 32 2.5%
he Incidence of Contralateral Iliac Venous Thrombosis After Stent-
ng Across the Iliocaval Confluence in Patients With Acute or Chronic
enous Outflow Obstruction
zabia A. Caliste, MD, Amanda L. Clark, BS, John P. Cullen, PhD, Craig
arins, MD, Ankur Chandra, MD, Jennifer Ellis, MD, Jason Kim, MD,
ichael Singh, MD, David L. Gillespie, MD. University of Rochester
edical Center, Division of Vascular Surgery, Rochester, NY
Objectives: Percutaneous transluminal angioplasty and stenting of the
liac veins is becoming a more common method of treating patients with
ymptomatic lower extremity venous outflow obstruction. Several questions
bout the conformation of these stents remain to be answered. One, in
articular, is whether these venous stents should extend into the vena cava or
top short of this in fear of causing further harm to the patient’s contralateral
eg.
Methods: We retrospectively reviewed prospectively collected data
rom 2008 to 2012 in patients with symptomatic iliocaval venous thrombo-
is who underwent percutaneous angioplasty and stenting. Data were col-
ected using the AVF venous stent database variables. Most patients were
aintained on full anticoagulation using warfarin (international normalized
atio 2-3) or low-molecular-weight heparin (weight-based daily or b.i.d.
osing). Patients with first time deep venous thrombosis were anticoagu-
ated for 6 months on average, and those with repeat deep venous throm-
osis were maintained on lifelong anticoagulation. Intraoperative anticoag-
lation was performed using intravenous heparin. Contralateral thrombosis
nd patency rates were recorded.
Results: A total of 183 iliocaval stents were placed in 66 patients
median age, 43; range 15-80 years), of which 63 patients experienced
hrombosis causing the venous outflow obstruction. Thirty patients experi-
nced acute venous thrombosis, 25 chronic, and nine acute on chronic.
orty-eight of 66 patients (72.7%) had patent stents noted on duplex
